$ALKS
Alkermes plc.

2023 Q2 Form 10-Q Financial Statement

#000156459023006240 Filed on April 26, 2023

View on sec.gov

Income Statement

Concept 2023 Q2 2023 Q1 2022 Q1
Revenue $617.4M $287.6M $278.5M
YoY Change 123.52% 3.25% 10.8%
Cost Of Revenue $63.26M $58.18M $55.16M
YoY Change 8.4% 5.47% 34.53%
Gross Profit $554.1M $229.4M $223.4M
YoY Change 154.36% 2.7% 6.17%
Gross Profit Margin 89.75% 79.77% 80.2%
Selling, General & Admin $205.3M $174.5M $145.1M
YoY Change 36.5% 20.29% 15.86%
% of Gross Profit 37.04% 76.05% 64.93%
Research & Development $98.09M $93.64M $93.15M
YoY Change 5.62% 0.52% 0.92%
% of Gross Profit 17.7% 40.81% 41.7%
Depreciation & Amortization $19.01M $18.71M $19.20M
YoY Change -1.96% -2.52% -2.06%
% of Gross Profit 3.43% 8.16% 8.59%
Operating Expenses $314.9M $268.1M $250.0M
YoY Change 29.47% 7.26% 10.17%
Operating Profit $239.2M -$47.49M -$26.59M
YoY Change -794.18% 78.65% 61.12%
Interest Expense $1.085M $5.288M -$1.277M
YoY Change -54.2% -514.1% 27.7%
% of Operating Profit 0.45%
Other Income/Expense, Net -$525.0K -$361.0K -$17.14M
YoY Change -143.5% -97.89% -2004.0%
Pretax Income $239.8M -$47.86M -$45.00M
YoY Change -821.06% 6.35% 140.63%
Income Tax $2.688M -$6.010M -$9.100M
% Of Pretax Income 1.12%
Net Earnings $237.1M -$41.85M -$35.90M
YoY Change -886.65% 16.55% 60.15%
Net Earnings / Revenue 38.4% -14.55% -12.89%
Basic Earnings Per Share $1.43 -$0.25 -$0.22
Diluted Earnings Per Share $1.38 -$0.25 -$221.0K
COMMON SHARES
Basic Shares Outstanding 166.1M 164.4M 162.5M
Diluted Shares Outstanding 171.6M 165.1M 162.5M

Balance Sheet

Concept 2023 Q2 2023 Q1 2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $829.0M $600.5M $528.9M
YoY Change 42.7% 13.54% -2.24%
Cash & Equivalents $665.8M $321.4M $282.6M
Short-Term Investments $163.3M $279.1M $246.3M
Other Short-Term Assets $44.45M $47.01M $61.02M
YoY Change -5.6% -22.96% -21.77%
Inventory $189.4M $185.0M $154.8M
Prepaid Expenses
Receivables $334.5M $277.6M $270.2M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $1.397B $1.110B $1.015B
YoY Change 33.59% 9.38% 0.88%
LONG-TERM ASSETS
Property, Plant & Equipment $431.2M $321.1M $336.7M
YoY Change 27.88% -4.64% -2.77%
Goodwill $92.87M $92.87M $92.87M
YoY Change 0.0% 0.0% 0.0%
Intangibles
YoY Change
Long-Term Investments $78.13M $92.08M $229.8M
YoY Change -56.36% -59.93% 166.0%
Other Assets $167.7M $14.91M $123.2M
YoY Change 1350.01% -87.9% 5.01%
Total Long-Term Assets $789.8M $812.7M $963.0M
YoY Change -13.34% -15.61% 10.41%
TOTAL ASSETS
Total Short-Term Assets $1.397B $1.110B $1.015B
Total Long-Term Assets $789.8M $812.7M $963.0M
Total Assets $2.187B $1.923B $1.978B
YoY Change 11.74% -2.79% 5.31%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $84.62M $37.15M $27.70M
YoY Change 111.29% 34.12% -23.27%
Accrued Expenses $396.3M $450.6M $426.7M
YoY Change 1.17% 5.58% 33.86%
Deferred Revenue $3.302M $2.193M
YoY Change -12.81%
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $3.000M $3.000M $3.000M
YoY Change 0.0% 0.0% 0.0%
Total Short-Term Liabilities $487.2M $492.9M $462.4M
YoY Change 11.1% 6.61% 26.4%
LONG-TERM LIABILITIES
Long-Term Debt $289.0M $289.6M $292.2M
YoY Change -0.87% -0.87% -0.86%
Other Long-Term Liabilities $130.6M $48.49M $147.9M
YoY Change 188.81% -67.22% -11.16%
Total Long-Term Liabilities $419.6M $338.1M $440.1M
YoY Change 24.59% -23.17% -4.58%
TOTAL LIABILITIES
Total Short-Term Liabilities $487.2M $492.9M $462.4M
Total Long-Term Liabilities $419.6M $338.1M $440.1M
Total Liabilities $906.7M $917.2M $902.5M
YoY Change 3.62% 1.63% 9.11%
SHAREHOLDERS EQUITY
Retained Earnings -$1.504B -$1.741B
YoY Change -6.41%
Common Stock $2.978B $2.940B
YoY Change 4.12%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $1.280B $1.006B $1.075B
YoY Change
Total Liabilities & Shareholders Equity $2.187B $1.923B $1.978B
YoY Change 11.74% -2.79% 5.31%

Cashflow Statement

Concept 2023 Q2 2023 Q1 2022 Q1
OPERATING ACTIVITIES
Net Income $237.1M -$41.85M -$35.90M
YoY Change -886.65% 16.55% 60.15%
Depreciation, Depletion And Amortization $19.01M $18.71M $19.20M
YoY Change -1.96% -2.52% -2.06%
Cash From Operating Activities $215.7M -$21.30M $21.68M
YoY Change -9454.29% -198.27% -148.02%
INVESTING ACTIVITIES
Capital Expenditures $9.705M $6.860M $7.791M
YoY Change -197.42% -11.95% -2.44%
Acquisitions
YoY Change
Other Investing Activities $130.6M $79.71M -$52.85M
YoY Change -526.98% -250.82% 77.95%
Cash From Investing Activities $120.8M $72.85M -$60.64M
YoY Change -398.11% -220.13% 60.72%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net $750.0K $750.0K
YoY Change 0.0%
Cash From Financing Activities 7.836M -22.62M -16.02M
YoY Change -47.53% 41.16% -207.22%
NET CHANGE
Cash From Operating Activities 215.7M -21.30M 21.68M
Cash From Investing Activities 120.8M 72.85M -60.64M
Cash From Financing Activities 7.836M -22.62M -16.02M
Net Change In Cash 344.4M 28.93M 21.68M
YoY Change -1333.9% 33.44% -131.91%
FREE CASH FLOW
Cash From Operating Activities $215.7M -$21.30M $21.68M
Capital Expenditures $9.705M $6.860M $7.791M
Free Cash Flow $206.0M -$28.16M $13.89M
YoY Change 2590.77% -302.79% -126.14%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001520262
CY2023Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2023Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q1 us-gaap Treasury Stock Common Value
TreasuryStockCommonValue
185606000
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q1 us-gaap Preferred Stock Value
PreferredStockValue
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2023Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2023Q1 dei Entity File Number
EntityFileNumber
001-35299
CY2023Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
L2
CY2023Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
Connaught House
CY2023Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
Dublin 4
CY2023Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
166121384
CY2023Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
321401000
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
292473000
CY2023Q1 us-gaap Inventory Net
InventoryNet
184984000
CY2022Q4 us-gaap Inventory Net
InventoryNet
181418000
CY2023Q1 us-gaap Contract With Customer Asset Net Current
ContractWithCustomerAssetNetCurrent
8429000
CY2022Q4 us-gaap Contract With Customer Asset Net Current
ContractWithCustomerAssetNetCurrent
8929000
CY2023Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
47008000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
43527000
CY2023Q1 us-gaap Assets Current
AssetsCurrent
1110058000
CY2022Q4 us-gaap Assets Current
AssetsCurrent
1130306000
CY2023Q1 us-gaap Receivables Net Current
ReceivablesNetCurrent
269178000
CY2023Q1 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
279058000
CY2022Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
315992000
CY2022Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
3000000
CY2022Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
290270000
CY2023Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
14906000
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
15722000
CY2023Q1 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
2193000
CY2023Q1 us-gaap Liabilities Current
LiabilitiesCurrent
492910000
CY2023Q1 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
289635000
CY2023Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
86112000
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
89829000
CY2023Q1 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
48494000
CY2023Q1 us-gaap Liabilities
Liabilities
917151000
CY2022Q4 us-gaap Liabilities
Liabilities
920225000
CY2023Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2023Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
50000000
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
50000000
CY2023Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2022Q4 us-gaap Treasury Stock Common Value
TreasuryStockCommonValue
160862000
CY2023Q1 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
2938726000
CY2022Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
2913099000
CY2022Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
95953000
CY2022Q1 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
145052000
CY2022Q1 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
8966000
CY2022Q1 us-gaap Costs And Expenses
CostsAndExpenses
305130000
CY2022Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
278545000
CY2022Q1 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
55159000
CY2022Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-26585000
CY2022Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
573000
CY2022Q4 us-gaap Receivables Net Current
ReceivablesNetCurrent
287967000
CY2022Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
162483000
CY2022Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-4511000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-41845000
CY2023Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
488000
CY2023Q1 us-gaap Profit Loss
ProfitLoss
-41845000
CY2023Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
18714000
CY2023Q1 us-gaap Share Based Compensation
ShareBasedCompensation
22643000
CY2023Q1 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-4287000
CY2022Q1 alks Proceeds From Contingent Consideration
ProceedsFromContingentConsideration
501000
CY2023Q1 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
23898000
CY2023Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
72850000
CY2023Q1 us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
2874000
CY2023Q1 us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
24744000
CY2023Q1 us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
750000
CY2023Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-22620000
CY2022Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-16024000
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
28928000
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-54987000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
292473000
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
321401000
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
282557000
CY2023Q1 us-gaap Noncash Or Part Noncash Acquisition Value Of Liabilities Assumed1
NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1
1762000
CY2022Q1 us-gaap Noncash Or Part Noncash Acquisition Value Of Liabilities Assumed1
NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1
4058000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
1043753000
CY2023Q1 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
2874000
CY2022Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
-1382000
CY2023Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-39085000
CY2022Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-40414000
CY2022Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
2431000
CY2023Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-361000
CY2022Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-18413000
CY2023Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
4966000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-35903000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
1075390000
CY2023Q1 dei Amendment Flag
AmendmentFlag
false
CY2023Q1 dei Document Type
DocumentType
10-Q
CY2023Q1 dei Document Period End Date
DocumentPeriodEndDate
2023-03-31
CY2023Q1 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
174477000
CY2022Q1 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
145052000
CY2023Q1 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
8800000
CY2023Q1 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
8800000
CY2022Q1 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
8966000
CY2023Q1 us-gaap Costs And Expenses
CostsAndExpenses
335089000
CY2023Q1 us-gaap Costs And Expenses
CostsAndExpenses
335089000
CY2022Q1 us-gaap Costs And Expenses
CostsAndExpenses
305130000
CY2023Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-47494000
CY2023Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-47494000
CY2022Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-26585000
CY2023Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
4966000
CY2022Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
573000
CY2023Q1 us-gaap Interest Expense
InterestExpense
5288000
CY2023Q1 us-gaap Interest Expense
InterestExpense
5288000
CY2022Q1 us-gaap Interest Expense
InterestExpense
2350000
CY2022Q1 us-gaap Interest Expense
InterestExpense
2350000
CY2022Q1 us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Asset1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1
-19067000
CY2022Q1 us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Asset1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1
-19067000
CY2023Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-39000
CY2023Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-39000
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
497742000
CY2022Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
42384000
CY2023Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
450000000
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
450000000
CY2023Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
171518796
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
168951193
CY2023Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
166058960
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
164377009
CY2023Q1 us-gaap Common Stock Value
CommonStockValue
1715000
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
1690000
CY2023Q1 us-gaap Treasury Stock Common Shares
TreasuryStockCommonShares
5459836
CY2022Q4 us-gaap Treasury Stock Common Shares
TreasuryStockCommonShares
4574184
CY2023Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-8129000
CY2022Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-10889000
CY2023Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1741130000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1699285000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
1005576000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
1043753000
CY2023Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
1922727000
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
1963978000
CY2023Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
287595000
CY2023Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
287595000
CY2022Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
278545000
CY2023Q1 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
58175000
CY2023Q1 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
58175000
CY2022Q1 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
55159000
CY2023Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
93637000
CY2023Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
93637000
CY2022Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
95953000
CY2023Q1 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
174477000
CY2023Q1 dei Entity Registrant Name
EntityRegistrantName
Alkermes plc.
CY2023Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
CY2023Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2023Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2023Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
98-1007018
CY2023Q1 dei Entity Address Address Line2
EntityAddressAddressLine2
1 Burlington Road
CY2023Q1 dei Entity Address Country
EntityAddressCountry
IE
CY2023Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
D04 C5Y6
CY2023Q1 dei City Area Code
CityAreaCode
353
CY2023Q1 dei Local Phone Number
LocalPhoneNumber
1-772-8000
CY2023Q1 dei Security12b Title
Security12bTitle
Ordinary shares, $0.01 par value
CY2023Q1 dei Trading Symbol
TradingSymbol
ALKS
CY2023Q1 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2023Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2023Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2023Q1 dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
CY2023Q1 dei Entity Small Business
EntitySmallBusiness
false
CY2023Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2023Q1 dei Entity Shell Company
EntityShellCompany
false
CY2023Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
321109000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
325361000
CY2023Q1 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
151232000
CY2022Q4 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
115602000
CY2023Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
111586000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
115855000
CY2023Q1 us-gaap Long Term Investments
LongTermInvestments
92083000
CY2022Q4 us-gaap Long Term Investments
LongTermInvestments
131610000
CY2023Q1 us-gaap Goodwill
Goodwill
92873000
CY2022Q4 us-gaap Goodwill
Goodwill
92873000
CY2023Q1 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
28880000
CY2022Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
37680000
CY2022Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
14691000
CY2023Q1 us-gaap Assets
Assets
1922727000
CY2022Q4 us-gaap Assets
Assets
1963978000
CY2023Q1 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
190149000
CY2022Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
220089000
CY2023Q1 alks Accrued Sales Discounts Allowances And Reserves
AccruedSalesDiscountsAllowancesAndReserves
282264000
CY2022Q4 alks Accrued Sales Discounts Allowances And Reserves
AccruedSalesDiscountsAllowancesAndReserves
252115000
CY2023Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
15304000
CY2022Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
6816000
CY2023Q1 us-gaap Long Term Debt Current
LongTermDebtCurrent
3000000
CY2022Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
2431000
CY2023Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-361000
CY2022Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-18413000
CY2023Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-47855000
CY2023Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-47855000
CY2022Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-44998000
CY2022Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-44998000
CY2023Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-6010000
CY2023Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-6010000
CY2022Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-9095000
CY2022Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-9095000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-41845000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-35903000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-35903000
CY2023Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.25
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.25
CY2022Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.22
CY2022Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.22
CY2023Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
165085000
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
165085000
CY2022Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
162483000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-41845000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-41845000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-35903000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-35903000
CY2023Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
2760000
CY2023Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
2760000
CY2022Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-4511000
CY2023Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-39085000
CY2022Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-40414000
CY2022Q1 us-gaap Profit Loss
ProfitLoss
-35903000
CY2022Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
19197000
CY2022Q1 us-gaap Share Based Compensation
ShareBasedCompensation
18343000
CY2023Q1 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-36117000
CY2022Q1 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-29301000
CY2022Q1 us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Asset1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1
-19067000
CY2023Q1 us-gaap Other Noncash Expense
OtherNoncashExpense
369000
CY2022Q1 us-gaap Other Noncash Expense
OtherNoncashExpense
371000
CY2023Q1 us-gaap Increase Decrease In Receivables
IncreaseDecreaseInReceivables
-18789000
CY2022Q1 us-gaap Increase Decrease In Receivables
IncreaseDecreaseInReceivables
-63290000
CY2023Q1 us-gaap Increase Decrease In Contract With Customer Asset
IncreaseDecreaseInContractWithCustomerAsset
-500000
CY2022Q1 us-gaap Increase Decrease In Contract With Customer Asset
IncreaseDecreaseInContractWithCustomerAsset
6849000
CY2023Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
2029000
CY2022Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
4285000
CY2023Q1 us-gaap Increase Decrease In Prepaid Expenses Other
IncreaseDecreaseInPrepaidExpensesOther
3697000
CY2022Q1 us-gaap Increase Decrease In Prepaid Expenses Other
IncreaseDecreaseInPrepaidExpensesOther
15351000
CY2023Q1 alks Increase Decrease In Right Of Use Asset
IncreaseDecreaseInRightOfUseAsset
-4269000
CY2022Q1 alks Increase Decrease In Right Of Use Asset
IncreaseDecreaseInRightOfUseAsset
-4129000
CY2023Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-30154000
CY2022Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-33414000
CY2023Q1 alks Increase Decrease In Accrued Sales Discount Allowances And Reserves
IncreaseDecreaseInAccruedSalesDiscountAllowancesAndReserves
30148000
CY2022Q1 alks Increase Decrease In Accrued Sales Discount Allowances And Reserves
IncreaseDecreaseInAccruedSalesDiscountAllowancesAndReserves
27956000
CY2022Q1 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-2980000
CY2023Q1 alks Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-4379000
CY2022Q1 alks Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-4411000
CY2023Q1 us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
5774000
CY2022Q1 us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
1819000
CY2023Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-21302000
CY2022Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
21678000
CY2023Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
6860000
CY2022Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
7791000
CY2022Q1 alks Return Of Investments
ReturnOfInvestments
485000
CY2022Q1 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
114615000
CY2023Q1 us-gaap Proceeds From Sale Maturity And Collections Of Investments
ProceedsFromSaleMaturityAndCollectionsOfInvestments
103608000
CY2022Q1 us-gaap Proceeds From Sale Maturity And Collections Of Investments
ProceedsFromSaleMaturityAndCollectionsOfInvestments
60779000
CY2022Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-60641000
CY2022Q1 us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
1795000
CY2022Q1 us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
17069000
CY2022Q1 us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
750000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
337544000
CY2023Q1 alks Receipt Of Company Stock For Exercise Of Stock Options Or To Satisfy Minimum Tax Withholding Obligations Related To Stock Based Awards Value
ReceiptOfCompanyStockForExerciseOfStockOptionsOrToSatisfyMinimumTaxWithholdingObligationsRelatedToStockBasedAwardsValue
-24744000
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
22778000
CY2023Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
488000
CY2023Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
2760000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-41845000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
1005576000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
1112584000
CY2022Q1 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
1795000
CY2022Q1 alks Receipt Of Company Stock For Exercise Of Stock Options Or To Satisfy Minimum Tax Withholding Obligations Related To Stock Based Awards Value
ReceiptOfCompanyStockForExerciseOfStockOptionsOrToSatisfyMinimumTaxWithholdingObligationsRelatedToStockBasedAwardsValue
-17069000
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
18494000
CY2022Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
-1382000
CY2022Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-4511000
CY2023Q1 us-gaap Nature Of Operations
NatureOfOperations
<p id="N1_COMPANY" style="margin-top:10pt;line-height:10pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">1. THE COMPANY</p> <p style="margin-top:10pt;margin-bottom:0pt;text-indent:2.71%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Alkermes plc is a fully-integrated, global biopharmaceutical company that applies its scientific expertise and proprietary technologies to research, develop and commercialize, both with partners and on its own, pharmaceutical products that are designed to address unmet medical needs of patients in the fields of neuroscience and oncology. Alkermes has a portfolio of proprietary commercial products focused on alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of product candidates in development for neurological disorders and cancer. Headquartered in Dublin, Ireland, the Company has a research and development (“R&amp;D”) center in Waltham, Massachusetts; an R&amp;D and manufacturing facility in Athlone, Ireland; and a manufacturing facility in Wilmington, Ohio.</p> <p style="margin-top:10pt;margin-bottom:0pt;text-indent:2.71%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On November 2, 2022, the Company announced its intent, as approved by its board of directors, to separate its neuroscience business and oncology business. The Company is exploring a separation of the oncology business into an independent, publicly-traded company (referred to herein as “Oncology Co.”) as part of an ongoing review of strategic alternatives for the oncology business. Following the potential separation, the Company would retain its focus on driving growth of its proprietary commercial products: LYBALVI, ARISTADA/ARISTADA INITIO and VIVITROL, and advancing the development of pipeline programs focused on neurological disorders. The Company also expects to retain manufacturing and royalty revenues related to its licensed products and third-party products using its proprietary technologies under license. Oncology Co. would focus on the discovery and development of cancer therapies, including the continued development of nemvaleukin alfa and the Company’s portfolio of novel, preclinical engineered cytokines. The separation, if consummated, is expected to be completed in the second half of 2023 and is subject to customary closing conditions, including final approval by the Company’s board of directors and receipt of a private letter ruling from the IRS and/or a tax opinion from the Company’s tax advisor.</p>
CY2022Q4 us-gaap Long Term Investments
LongTermInvestments
131610000
CY2022Q4 alks Marketable Securities At Amortized Cost
MarketableSecuritiesAtAmortizedCost
456951000
CY2022Q4 alks Marketable Investments Securities Unrealized Gain Loss
MarketableInvestmentsSecuritiesUnrealizedGainLoss
16000
CY2022Q4 alks Marketable Securities Continuous Unrealized Loss Position Less Than12 Months Aggregate Losses
MarketableSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsAggregateLosses
3185000
CY2022Q4 alks Marketable Securities Continuous Unrealized Loss Position12 Months Or Longer Aggregate Losses
MarketableSecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAggregateLosses
6180000
CY2022Q4 us-gaap Investments Fair Value Disclosure
InvestmentsFairValueDisclosure
447602000
CY2023Q1 alks Number Of Investment Securities
NumberOfInvestmentSecurities
207
CY2023Q1 alks Number Of Unrealized Investment Securities
NumberOfUnrealizedInvestmentSecurities
239
CY2023Q1 us-gaap Debt Securities Available For Sale Unrealized Loss Position
DebtSecuritiesAvailableForSaleUnrealizedLossPosition
371100000
CY2023Q1 us-gaap Operating Lease Expense
OperatingLeaseExpense
4300000
CY2022Q1 us-gaap Operating Lease Expense
OperatingLeaseExpense
4100000
CY2023Q1 us-gaap Use Of Estimates
UseOfEstimates
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Use of Estimates</p> <p style="margin-top:10pt;margin-bottom:0pt;text-indent:2.71%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of the Company’s condensed consolidated financial statements in accordance with GAAP requires that Company management make estimates, judgments and assumptions that may affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. On an ongoing basis, the Company evaluates its estimates, judgments and methodologies, including, but not limited to, those related to revenue from contracts with its customers and related allowances, impairment and amortization of intangibles and long-lived assets, share-based compensation, income taxes including the valuation allowance for deferred tax assets, valuation of </p> <p style="margin-top:10pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">investments</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, contingent consideration</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and litigation. The Company bases its estimates on historical experience and on various other assumptions that are believed to be reasonable, the results of which form the basis for making judgments about the carrying values of</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">assets and liabilities. Actual results may differ from these estimates under </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">different </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">conditions or using different assumptions</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</span></p>
CY2023Q1 us-gaap Number Of Reportable Segments
NumberOfReportableSegments
1
CY2023Q1 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
103608000
CY2022Q1 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
60779000
CY2022Q4 us-gaap Contract With Customer Asset Net
ContractWithCustomerAssetNet
8929000
CY2023Q1 us-gaap Contract With Customer Asset Purchase
ContractWithCustomerAssetPurchase
10115000
CY2023Q1 us-gaap Contract With Customer Asset Reclassified To Receivable
ContractWithCustomerAssetReclassifiedToReceivable
10615000
CY2023Q1 us-gaap Contract With Customer Asset Net
ContractWithCustomerAssetNet
8429000
CY2022Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
10701000
CY2023Q1 alks Contract With Customer Liability Additions
ContractWithCustomerLiabilityAdditions
-934000
CY2023Q1 us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
-3354000
CY2023Q1 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
6413000
CY2023Q1 us-gaap Debt Securities Available For Sale Amortized Cost Current
DebtSecuritiesAvailableForSaleAmortizedCostCurrent
282331000
CY2023Q1 alks Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax Current
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxCurrent
168000
CY2023Q1 alks Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss Current
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLossCurrent
201000
CY2023Q1 alks Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss Current
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLossCurrent
3240000
CY2023Q1 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
279058000
CY2023Q1 us-gaap Debt Securities Available For Sale Amortized Cost Noncurrent
DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent
93091000
CY2023Q1 alks Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss Noncurrent
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLossNoncurrent
1079000
CY2023Q1 alks Debt Securities Available For Sale Continuous Unrealized Loss Position Greater Than12 Months Accumulated Loss Non Current
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionGreaterThan12MonthsAccumulatedLossNonCurrent
1749000
CY2023Q1 us-gaap Available For Sale Securities Debt Securities Noncurrent
AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
90263000
CY2023Q1 alks Long Term Investment Amortized Cost
LongTermInvestmentAmortizedCost
94911000
CY2023Q1 alks Long Term Investment Securities Continuous Unrealized Loss Position Less Than12 Months Aggregate Losses
LongTermInvestmentSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsAggregateLosses
1079000
CY2023Q1 alks Long Term Investment Securities Continuous Unrealized Loss Position More Than12 Months Aggregate Losses
LongTermInvestmentSecuritiesContinuousUnrealizedLossPositionMoreThan12MonthsAggregateLosses
1749000
CY2023Q1 us-gaap Long Term Investments
LongTermInvestments
92083000
CY2023Q1 alks Marketable Securities At Amortized Cost
MarketableSecuritiesAtAmortizedCost
377242000
CY2023Q1 alks Marketable Investments Securities Unrealized Gain Loss
MarketableInvestmentsSecuritiesUnrealizedGainLoss
168000
CY2023Q1 alks Marketable Securities Continuous Unrealized Loss Position Less Than12 Months Aggregate Losses
MarketableSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsAggregateLosses
1280000
CY2023Q1 alks Marketable Securities Continuous Unrealized Loss Position12 Months Or Longer Aggregate Losses
MarketableSecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAggregateLosses
4989000
CY2023Q1 us-gaap Investments Fair Value Disclosure
InvestmentsFairValueDisclosure
371141000
CY2022Q4 us-gaap Debt Securities Available For Sale Amortized Cost Current
DebtSecuritiesAvailableForSaleAmortizedCostCurrent
320583000
CY2022Q4 alks Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax Current
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxCurrent
16000
CY2022Q4 alks Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss Current
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLossCurrent
718000
CY2022Q4 alks Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss Current
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLossCurrent
3889000
CY2022Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
315992000
CY2022Q4 us-gaap Debt Securities Available For Sale Amortized Cost Noncurrent
DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent
134548000
CY2022Q4 alks Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss Noncurrent
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLossNoncurrent
2467000
CY2022Q4 alks Debt Securities Available For Sale Continuous Unrealized Loss Position Greater Than12 Months Accumulated Loss Non Current
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionGreaterThan12MonthsAccumulatedLossNonCurrent
2291000
CY2022Q4 us-gaap Available For Sale Securities Debt Securities Noncurrent
AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
129790000
CY2022Q4 alks Long Term Investment Amortized Cost
LongTermInvestmentAmortizedCost
136368000
CY2022Q4 alks Long Term Investment Securities Continuous Unrealized Loss Position Less Than12 Months Aggregate Losses
LongTermInvestmentSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsAggregateLosses
2467000
CY2022Q4 alks Long Term Investment Securities Continuous Unrealized Loss Position More Than12 Months Aggregate Losses
LongTermInvestmentSecuritiesContinuousUnrealizedLossPositionMoreThan12MonthsAggregateLosses
2291000
CY2023Q1 us-gaap Available For Sale Securities Debt Maturities Within One Year Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost
272122000
CY2023Q1 us-gaap Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
268811000
CY2023Q1 us-gaap Held To Maturity Securities Debt Maturities Within One Year Net Carrying Amount
HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearNetCarryingAmount
1820000
CY2023Q1 us-gaap Held To Maturity Securities Debt Maturities Within One Year Fair Value
HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearFairValue
1820000
CY2023Q1 us-gaap Available For Sale Securities Debt Maturities After One Through Five Years Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost
103300000
CY2023Q1 us-gaap Available For Sale Securities Debt Maturities After One Through Five Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
100510000
CY2023Q1 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
375422000
CY2023Q1 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
369321000
CY2023Q1 us-gaap Held To Maturity Securities
HeldToMaturitySecurities
1820000
CY2023Q1 us-gaap Held To Maturity Securities Fair Value
HeldToMaturitySecuritiesFairValue
1820000
CY2023Q1 alks Fair Value Recurring Basis Assets Or Liabilities Transfers Between Level One To Level Two
FairValueRecurringBasisAssetsOrLiabilitiesTransfersBetweenLevelOneToLevelTwo
0
CY2023Q1 alks Fair Value Recurring Basis Assets Or Liabilities Transfers Between Level Two To Level One
FairValueRecurringBasisAssetsOrLiabilitiesTransfersBetweenLevelTwoToLevelOne
0
CY2023Q1 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Value
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue
0
CY2023Q1 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
59045000
CY2022Q4 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
61064000
CY2023Q1 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
74661000
CY2022Q4 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
76228000
CY2023Q1 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
51278000
CY2022Q4 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
44126000
CY2023Q1 us-gaap Inventory Net
InventoryNet
184984000
CY2022Q4 us-gaap Inventory Net
InventoryNet
181418000
CY2023Q1 alks Inventory Finished Goods Net Of Reserves Located At Third Party Warehouse And Shipping Service Provider
InventoryFinishedGoodsNetOfReservesLocatedAtThirdPartyWarehouseAndShippingServiceProvider
32600000
CY2022Q4 alks Inventory Finished Goods Net Of Reserves Located At Third Party Warehouse And Shipping Service Provider
InventoryFinishedGoodsNetOfReservesLocatedAtThirdPartyWarehouseAndShippingServiceProvider
30900000
CY2023Q1 alks Lessee Operating Lease Liability Payments Due After Year Four
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour
69474000
CY2022Q4 alks Lessee Operating Lease Liability Payments Due After Year Four
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour
69474000
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
137573000
CY2022Q4 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
141875000
CY2023Q1 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
36157000
CY2022Q4 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
36324000
CY2023Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
101416000
CY2022Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
105551000
CY2023Q1 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0527
CY2023Q1 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P8Y6M10D
CY2023Q1 us-gaap Operating Lease Payments
OperatingLeasePayments
4400000
CY2022Q1 us-gaap Operating Lease Payments
OperatingLeasePayments
4400000
CY2023Q1 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
764669000
CY2022Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
759019000
CY2023Q1 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
443560000
CY2022Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
433658000
CY2023Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
321109000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
325361000
CY2023Q1 us-gaap Goodwill Gross
GoodwillGross
92873000
CY2023Q1 us-gaap Goodwill
Goodwill
92873000
CY2023Q1 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
583750000
CY2023Q1 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
554870000
CY2023Q1 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
28880000
CY2023Q1 us-gaap Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year
FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear
35000000.0
CY2023Q1 us-gaap Finite Lived Intangible Assets Amortization Expense Next Twelve Months
FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
1000000.0
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
12306000
CY2022Q4 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
16665000
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
16627000
CY2022Q4 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
16608000
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
16874000
CY2022Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
16855000
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
12786000
CY2022Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
12767000
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
9506000
CY2022Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
9506000
CY2023Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
37147000
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
32843000
CY2023Q1 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
47700000
CY2022Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
79085000
CY2023Q1 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
105302000
CY2022Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
108161000
CY2023Q1 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
190149000
CY2022Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
220089000
CY2023Q1 alks Accrued Sales Discounts Allowances And Reserves
AccruedSalesDiscountsAllowancesAndReserves
282264000
CY2022Q4 alks Accrued Sales Discounts Allowances And Reserves
AccruedSalesDiscountsAllowancesAndReserves
252115000
CY2023Q1 us-gaap Loss Contingency Damages Sought Value
LossContingencyDamagesSoughtValue
66000000.0
CY2023Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
22643000
CY2022Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
18343000
CY2023Q1 us-gaap Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount
EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
3400000
CY2022 us-gaap Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount
EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
3300000
CY2023Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
19100000
CY2022Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
19420000
CY2023Q1 us-gaap Loss Contingency Accrual Provision
LossContingencyAccrualProvision
0

Files In Submission

Name View Source Status
0001564590-23-006240-index-headers.html Edgar Link pending
0001564590-23-006240-index.html Edgar Link pending
0001564590-23-006240.txt Edgar Link pending
0001564590-23-006240-xbrl.zip Edgar Link pending
alks-10q_20230331.htm Edgar Link pending
alks-20230331.xsd Edgar Link pending
alks-ex101_78.htm Edgar Link pending
alks-ex102_77.htm Edgar Link pending
alks-ex311_8.htm Edgar Link pending
alks-ex312_10.htm Edgar Link pending
alks-ex321_7.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
g2ej2lrbumav000001.jpg Edgar Link pending
g2ej2lrbumav000002.jpg Edgar Link pending
g2ej2lrbumav000003.jpg Edgar Link pending
g2ej2lrbumav000004.jpg Edgar Link pending
grk3d14m5kog000001.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
alks-20230331_cal.xml Edgar Link unprocessable
alks-20230331_pre.xml Edgar Link unprocessable
alks-20230331_def.xml Edgar Link unprocessable
alks-20230331_lab.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
alks-10q_20230331_htm.xml Edgar Link completed
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending